We report that 79.7% of OPAT patients being treated for BJI at our centre would be eligible for oral antibiotics” Marks et al (2019).
Abstract:
The OVIVA study demonstrated non-inferiority for managing bone and joint infections (BJI) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJI at our centre would be eligible for oral antibiotics, saving median 19.5 IV antibiotic days (IQR 8.5-37) and GBP 1,234 (IQR 569-2,594) per patient.
You may also be interested in…
[rp4wp]
Reference:
Marks, M., Bell, L.C.K., Jones, I., Rampling, T., Kranzer, K., Morris-Jones, S., Logan, S. and Pollara, G. (2019) Clinical and economic impact of implementing OVIVA criteria on patients with bone and joint infections in OPAT. Clinical Infectious Diseases. October 11th. doi: 10.1093/cid/ciz991. [Epub ahead of print].